Physician

James Xunhai Xu, M.D.

According to 2025 Medicare claims, James Xu, M.D. (NPI: 1104003342) practices hematology/oncology in the Frederick-Gaithersburg-Bethesda, MD market, with the plurality of this provider's patient population coming from Montgomery, MD. This provider's primary affiliated billing organization is POTOMAC ONCOLOGY & HEMATOLOGY, LLC (NPI: 1962947937; TIN: 813805288) and primary practice location at 20852-9998.

Xu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 615 traditional Medicare patients, billed 199,785 HCPCS/CPT codes, and received $2,521,188 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,252 prescription claims across 175 beneficiaries totaling $2,624,024 in drug costs, led by Lenalidomide (Lenalidomide). Open Payments data shows 83 records totaling $2,098. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $107,482 to $2,521,188. Similarly, Part D prescription costs have moved sharply higher in recent years, from $3,832 to $2,624,024. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	194	8,208	$107,482
2016	194	24,685	$347,952
2017	223	12,853	$232,658
2018	288	67,465	$707,669
2019	398	173,672	$1,075,265
2020	362	117,453	$1,851,798
2021	461	145,787	$1,794,802
2022	554	266,977	$2,724,177
2023	609	313,324	$2,698,285
2024	615	199,785	$2,521,188

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	13	34	$3,832
2016	28	168	$55,107
2017	39	364	$296,499
2018	61	446	$443,548
2019	76	553	$658,928
2020	76	633	$1,013,204
2021	100	616	$1,572,523
2022	127	973	$1,793,702
2023	131	1,053	$2,235,996
2024	175	1,252	$2,624,024

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	317	1,149	$118
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	330	901	$79
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	203	784	$72
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	392	1,432	$15
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	436	3,590	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	34	952	$582,147
Venclexta	Venetoclax	15	335	$174,563
Eliquis	Apixaban	192	9,365	$174,457
Avastin	Bevacizumab	15	315	$113,843
Abiraterone Acetate	Abiraterone Acetate	40	1,200	$58,244

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	83	$2,098	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for James Xunhai Xu, M.D.?

Tedicare shows public-source Medicare data for James Xunhai Xu, M.D. (NPI 1104003342), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James Xunhai Xu, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to James Xunhai Xu, M.D.?

James Xunhai Xu, M.D. is linked to POTOMAC ONCOLOGY & HEMATOLOGY, LLC (billing NPI 1962947937) in the available physician profile data.

Does James Xunhai Xu, M.D. have Open Payments data?

James Xunhai Xu, M.D. has 83 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.